Skip to main content

Terrascend Corp(TSND-T)
TSX

Today's Change
Real-Time Last Update

TerrAscend: Stocks Analysts Recently Downgraded on TSX (TSND)

AI-generated - The Globe and Mail - Tue Jan 2, 3:58AM CST

TerrAscend Corp is among the group of Toronto Stock Exchange stocks recently downgraded by analysts. This means each stock on this list has seen its averge consensus value drop in the last week so at least one analyst has downgraded their view on these stocks.

This report is generated monthly. It displays the number of analysts along with their buy-hold-sell ratings for the company. A company is included in this list when its mean rating decreases from the previous week. Stocks in this category are generally sold to preserve capital.

Companies can get downgraded for a number of reasons - but primarily due to reduced future earnings potential due to loss of contracts, new faltering product lines or increasing costs relative to revenue or financial risk.

SymbolNameBuyOut PerformHoldUnder PerformSellNo OpinionMean RatingPrev Mean RatingMean Label
TSNDTerrAscend Corp4100004.84.8333Buy

All data provided as of December 22, 2023.

More about TerrAscend Corp

TerrAscend Corp is a company focused on creating and delivering quality cannabis products and services that meet the evolving needs of patients. It also provides education and support programs to physicians and patients through healthcare professionals. It has one operating segment, being cultivation, production, and sale of cannabis products, with subsidiaries located in Canada and the United States.

TerrAscend Corp is listed under TSND on the Toronto Stock Exchange.

Artificial intelligence at Report on Business

Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.

More from The Globe